AML with an immunophenotypic signature similar to that of multipotent progenitors (MPPs) is enriched in mutations in epigenetic modifiers, spliceosomes, and myeloid transcription factors, mainly RUNX1 and ETV6. Here, RUNX1 is linked to acute myeloid leukemia.